Glioblastoma kills most patients within 15 months of diagnosis, and the drugs approved to treat it have barely moved that number in two decades. Against that backdrop, UP Oncolytics has secured $2.5 million in NIH Phase II SBIR Fast-Track funding to push an engineered Zika virus therapy closer to a first human trial, building on an earlier $500,000 Phase I award from the same mechanism.
The appeal of Zika as an oncology tool is biological: the virus naturally crosses the blood-brain barrier, the membrane that blocks most chemotherapy from reaching brain tumors. UP Oncolytics is adapting it to target and destroy glioblastoma cells while sparing healthy tissue, a strategy the company’s preclinical studies have shown to be active against tumors. The FDA has already granted Orphan Drug Designation to one of the company’s oncolytic virus strains for malignant gliomas, a step that confers development incentives but says nothing about efficacy or approval. The two-year funding tranche will be spent completing the preclinical package needed to file an Investigational New Drug application with the FDA, which is the formal gateway to enrolling patients.
The unmet need here is real and measurable. The Stupp protocol, the standard-of-care regimen combining radiation with temozolomide that set the benchmark in 2005, produced a median overall survival of 14.6 months in newly diagnosed patients. UP Oncolytics’ source data cites approximately 15 months as the current median, meaning decades of subsequent work has added little. Other oncolytic virus programs, including DNX-2401 combined with pembrolizumab in recurrent glioblastoma, have reached clinical testing, so UP Oncolytics is entering a field with active competitors rather than an empty one. What distinguishes this program is the specific viral vector: Zika’s neurotropism is the property the company is betting on as a delivery mechanism that conventional drugs cannot replicate.
The IND application is now the concrete marker to watch. Filing it would trigger FDA review of whether the safety data on an attenuated, therapeutically re-engineered Zika strain is sufficient to expose patients to it, a question whose answer will determine whether this approach ever leaves preclinical settings. With roughly 13,000 Americans diagnosed with glioblastoma each year and only about 5% surviving five years, the agency has incentive to move quickly on a credible application.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
